Lexeo Therapeutics stock gets Stifel buy rating on PKP2 data
Stifel reiterated a Buy rating and $17 price target for Lexeo Therapeutics (LXEO) after positive PKP2 program data. The stock is down 71% YTD but analysts see strong upside. Lexeo announced a $8.3M acquisition of Mantle Therapeutics. Multiple analysts maintain bullish ratings with targets up to $35.
How this was made
The 30-second read
Why it matters
The new PKP2 cohort results and the Mantle Therapeutics acquisition provide fresh catalysts that could re‑price the stock.
Market read
The article introduces primary clinical data and an acquisition, both likely to move LXEO price in the short term.
What to watch
Potential regulatory delays or competition from other gene‑therapy programs.
Background
Lexeo Therapeutics (NASDAQ:LXEO) is a micro‑cap biotech focused on gene‑editing therapies for cardiomyopathies.
Ticker impact
Stifel reiterated a Buy rating and raised the price target to $17 after Lexeo Therapeutics presented new PKP2 trial data showing ~80% improvement in non‑sustained ventricular tachycardia.
upward pressure as the market prices in the improved efficacy data and higher target price.
Analyst upgrades and a clear regulatory path to accelerated approval provide a concrete catalyst; the acquisition adds pipeline depth.
Market effects
The PKP2 data may boost sentiment for the broader cardiac‑gene‑therapy sector.
U.S. biotech investors could see increased buying in small‑cap gene‑therapy stocks.
Limited to biotech niche; no broad market effect.
Counterpoint
If the efficacy data does not translate to a pivotal trial, the price could fall sharply.
Key entities
- companyLexeo Therapeutics
Developer of PKP2 gene‑editing therapy.
- analystStifel
Equity research firm that reiterated a Buy rating.

